. Author manuscript; available in PMC: 2021 Jul 1.

Published in final edited form as: Trends Cancer. 2020 Mar 31;6(7):580–592. doi: 10.1016/j.trecan.2020.02.003

Table 3.

Clinical Trials with the Indicated Clinicaltrial.gov NCT IDs Combining Immune Checkpoint Inhibitors and Epigenetic Targeting Agents^a

Epigenetic targeting agent	Immune checkpoint inhibitor
Epigenetic targeting agent	Ipilimumab (anti-CTLA4)	Nivolumab (anti-PD-1)	Pembrolizumab (anti-PD-1)	Atezolizumab (anti-PD-L1)	Avelumab (anti-PD-L1)	Durvalumab (anti-PD-L1)
DNMTi
Azacitidine	02530463, 02397720	02530463, 02397720, 01928576	03264404, 03769532, 03094637, 02260440, 02816021, 02845297, 02546986, 02959437, 02900560, 02512172	02508870	03390296, 03699384, 02953561, 03390296, 02951156	02811497, 03019003, 02811497, 02775903, 03161223, 02117219, 02250326, 03019003
Decitabine	02890329	02664181, 03358719	03445858, 02996474, 03969446, 03240211, 02957968, 03233724		03395873
Guadecitabine	02608437, 02890329	03576963	02901899, 02998567, 03220477	02892318, 02935361, 03179943, 03206047		03308396, 03257761, 03085849
HDACi
Vorinostat			02619253, 03150329, 03426891, 02395627
Romidepsin		02393794	03278782, 02512172			03161223
Panobinostat	02032810
Chidamide	02718066
Mocetinostat	03565406	03565406, 02954991	03220477			02805660, 02993991
Valproic acid		02648633			03357757
Abexinostat			03590054
Entinostat	03552380, 02453620	03838042, 03552380, 02453620, 03250273, 01928576	03179930, 02936752, 02909452, 03765229, 02437136, 02697630, 03978624	02708680, 03280563	02915523
Domatinostat					03812796
BETi
INCB057643			02959437
BMS-986158		024-19417
KMT6Ai
Tazemetostat			03854474	02220842
CPI-1205	03525795
KDM1Ai
INCB059872		02712905	02959437

In addition, sintilimab (anti-PD-1) is being tested in combination with chidamide (HDACi) (NCT03820596), and tremelimumab (anti-CTLA-4) is being tested in combination with azacitidine (DNMTi) (NCT03019003) and guadecitabine (DNMTi) (NCT03085849).